Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 53.600
Filtrer
1.
BMJ Open Respir Res ; 11(1)2024 Aug 03.
Article de Anglais | MEDLINE | ID: mdl-39097412

RÉSUMÉ

BACKGROUND: Pneumonia due to typical bacterial, atypical bacterial and viral pathogens can be difficult to clinically differentiate. Host response-based diagnostics are emerging as a complementary diagnostic strategy to pathogen detection. METHODS: We used murine models of typical bacterial, atypical bacterial and viral pneumonia to develop diagnostic signatures and understand the host's response to these types of infections. Mice were intranasally inoculated with Streptococcus pneumoniae, Mycoplasma pneumoniae, influenza or saline as a control. Peripheral blood gene expression analysis was performed at multiple time points. Differentially expressed genes were used to perform gene set enrichment analysis and generate diagnostic signatures. These murine-derived signatures were externally validated in silico using human gene expression data. The response to S. pneumoniae was the most rapid and robust. RESULTS: Mice infected with M. pneumoniae had a delayed response more similar to influenza-infected animals. Diagnostic signatures for the three types of infection had 0.94-1.00 area under the receiver operator curve (auROC). Validation in five human gene expression datasets revealed auROC of 0.82-0.96. DISCUSSION: This study identified discrete host responses to typical bacterial, atypical bacterial and viral aetiologies of pneumonia in mice. These signatures validated well in humans, highlighting the conserved nature of the host response to these pathogen classes.


Sujet(s)
Modèles animaux de maladie humaine , Mycoplasma pneumoniae , Pneumopathie à mycoplasmes , Streptococcus pneumoniae , Animaux , Humains , Souris , Streptococcus pneumoniae/génétique , Streptococcus pneumoniae/isolement et purification , Pneumopathie à mycoplasmes/diagnostic , Mycoplasma pneumoniae/génétique , Mycoplasma pneumoniae/isolement et purification , Femelle , Pneumonie à pneumocoques/microbiologie , Infections à Orthomyxoviridae/immunologie , Courbe ROC , Analyse de profil d'expression de gènes , Pneumopathie virale/diagnostic , Pneumopathie virale/immunologie , Souris de lignée C57BL , Pneumopathie bactérienne/microbiologie , Pneumopathie bactérienne/diagnostic , Interactions hôte-pathogène
2.
Nat Commun ; 15(1): 6503, 2024 Aug 01.
Article de Anglais | MEDLINE | ID: mdl-39090095

RÉSUMÉ

The COVID-19 pandemic has led to the deaths of millions of people and severe global economic impacts. Small molecule therapeutics have played an important role in the fight against SARS-CoV-2, the virus responsible for COVID-19, but their efficacy has been limited in scope and availability, with many people unable to access their benefits, and better options are needed. EDP-235 is specifically designed to inhibit the SARS-CoV-2 3CLpro, with potent nanomolar activity against all SARS-CoV-2 variants to date, as well as clinically relevant human and zoonotic coronaviruses. EDP-235 maintains potency against variants bearing mutations associated with nirmatrelvir resistance. Additionally, EDP-235 demonstrates a ≥ 500-fold selectivity index against multiple host proteases. In a male Syrian hamster model of COVID-19, EDP-235 suppresses SARS-CoV-2 replication and viral-induced hamster lung pathology. In a female ferret model, EDP-235 inhibits production of SARS-CoV-2 infectious virus and RNA at multiple anatomical sites. Furthermore, SARS-CoV-2 contact transmission does not occur when naïve ferrets are co-housed with infected, EDP-235-treated ferrets. Collectively, these results demonstrate that EDP-235 is a broad-spectrum coronavirus inhibitor with efficacy in animal models of primary infection and transmission.


Sujet(s)
Antiviraux , COVID-19 , Protéases 3C des coronavirus , SARS-CoV-2 , Réplication virale , Animaux , Cricetinae , Femelle , Humains , Mâle , Antiviraux/pharmacologie , Chlorocebus aethiops , Protéases 3C des coronavirus/antagonistes et inhibiteurs , Protéases 3C des coronavirus/métabolisme , COVID-19/virologie , COVID-19/transmission , Traitements médicamenteux de la COVID-19 , Modèles animaux de maladie humaine , Furets , Lactames , Leucine , Poumon/virologie , Poumon/effets des médicaments et des substances chimiques , Poumon/anatomopathologie , Mesocricetus , Nitriles , Composés chimiques organiques , Pandémies/prévention et contrôle , Pneumopathie virale/traitement médicamenteux , Pneumopathie virale/virologie , Pneumopathie virale/transmission , Pneumopathie virale/prévention et contrôle , Proline , SARS-CoV-2/effets des médicaments et des substances chimiques , SARS-CoV-2/génétique , SARS-CoV-2/physiologie , Cellules Vero , Réplication virale/effets des médicaments et des substances chimiques
3.
J Pak Med Assoc ; 74(6 (Supple-6)): S13-S17, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-39018133

RÉSUMÉ

OBJECTIVE: To evaluate the factors associated with mortality among coronavirus disease-2019 patients with preexisting hypertension. METHODS: The retrospective, cross-sectional study was conducted from June 15 to July 7, 2021, after approval from Dr Soetomo General Province Hospital, Indonesia, and comprised data from the coronavirus disease-2019 registry in the East Java province of Indonesia from March 2020 to June 2021. Data was collected for adult patients infected by coronavirus disease-2019 with pre-existing hypertension Data was analysed using SPSS 23. RESULTS: Of the 2,732 patients in the registry, 425(15.6%) with median age 56.5 years (interquartile range: 50-64 years) had pre-existing hypertension. Of them, 251(59.06%) were males, and 110(25.9%) had died while in hospital. Mortality was associated with older age; higher white blood cell counts at admission and lower platelet count (p<0.05). In addition, electrocardiogram parameters associated with mortality were faster heart rate and ST abnormality (p<0.05). CONCLUSIONS: Older age, high white blood cell level, lower platelet count, faster heart rate, and ST abnormality at admission were found to be the predictors of mortality among hospitalised coronavirus disease-2019 patients with pre-existing hypertension.


Sujet(s)
COVID-19 , Électrocardiographie , Hypertension artérielle , Pandémies , SARS-CoV-2 , Humains , COVID-19/mortalité , COVID-19/complications , COVID-19/épidémiologie , Mâle , Adulte d'âge moyen , Indonésie/épidémiologie , Femelle , Hypertension artérielle/épidémiologie , Hypertension artérielle/mortalité , Hypertension artérielle/complications , Études transversales , Études rétrospectives , Infections à coronavirus/mortalité , Infections à coronavirus/complications , Infections à coronavirus/épidémiologie , Infections à coronavirus/diagnostic , Pneumopathie virale/mortalité , Pneumopathie virale/complications , Pneumopathie virale/épidémiologie , Pneumopathie virale/diagnostic , Betacoronavirus , Sujet âgé , Facteurs âges , Adulte , Numération des leucocytes , Facteurs de risque , Numération des plaquettes , Mortalité hospitalière
4.
Pol Merkur Lekarski ; 52(3): 337-346, 2024.
Article de Anglais | MEDLINE | ID: mdl-39007473

RÉSUMÉ

At the beginning of 2020, the world was faced with the challenge of the coronavirus disease 2019 (COVID-19) pandemic announced by the WHO on March 11, caused by the betacoronavirus type 2 of the severe acute respiratory syndrome (SARS-CoV-2), which had profound health, sociological and even economic consequences. The quickly implemented and large-scale research resulted in the introduction of widely available vaccines that reduced the further development of the pandemic and antivirals against SARS-CoV-2. Currently, 11 antiviral drugs (Tixagevimab/Cilgavimab, Regdanvimab, Casirivimab/Imdevimab, Sotrovimab, Nirmatrelvir/Ritonavir, Remdesivir, Molnupiravir, Baricitinib, Anakinra, Tocilizumab, Vilobelimab) have been approved or conditionally approved by the European Medicines Agency and/or by the Food and Drug Administration and are available on the pharmaceutical market. The progress in the pathophysiological description of the SARS-CoV-2 infection has allowed the identif i cation of potential targets for drugs against SARS-CoV-2: inhibitors of intracellular entry of the virus (the interaction between the viral spike (S) protein and the cellular angiotensin converting enzyme-2; ACE2 receptor), inhibitors of viral and cellular proteases, and immunomodulatory drugs (antagonists of pro-inf l ammatory cytokines or complement components). Novel agents against SARS-CoV-2 are also sought among the previously routinely used drugs as their repositioning and among plant-derived compounds. It is expected that ongoing research should result in the introduction of new drugs used in COVID-19 in the near future. The article brief l y describes the current epidemiological situation regarding COVID-19 and the currently used vaccines. Moreover, the paper outlines currently used and researched potential drugs in the pharmacotherapy of this disease.


Sujet(s)
Antiviraux , Traitements médicamenteux de la COVID-19 , COVID-19 , Pandémies , SARS-CoV-2 , Humains , Antiviraux/usage thérapeutique , COVID-19/épidémiologie , Pneumopathie virale/traitement médicamenteux , Pneumopathie virale/épidémiologie , Infections à coronavirus/traitement médicamenteux , Infections à coronavirus/épidémiologie
5.
S Afr Med J ; 114(6b): e1385, 2024 Jun 24.
Article de Anglais | MEDLINE | ID: mdl-39041528

RÉSUMÉ

BACKGROUND: The COVID-19 pandemic highlighted the weakness of relying on in-person tuition in higher education. Massive open online courses (MOOCs) have been a successful addition to higher education. In this study, educators had to replace a planned elective in the medical curriculum with an online option during the pandemic. The roles of the competency framework of the Health Professions Council of South Africa (HPCSA) (Leader and Manager, Health Advocate, Professional, Communicator, Collaborator, Scholar, and Healthcare Practitioner) were used to guide its development. This elective emphasised the non-clinical roles of medical practitioners and was offered in 2020 and 2021. OBJECTIVES: To describe the choices of third-year medical students and time spent participating in a modified online elective in 2020 and 2021. METHODS: A descriptive cross-sectional study design was used, involving the participation of 629 medical students. Data were collected and analysed from three primary sources: registration data from LinkedIn Learning, data from the Foundation for Professional Development, and self-reported estimates by students of the average time spent on selected courses. Data included identification of the associated competency acquired. Data analysis was conducted using Python, version 3.10.11. RESULTS: The course choices of 629 students were analysed. In 2020 there were 300 participants and in 2021 there were 329. All the students had one compulsory inclusion in the elective (Management and Leadership Short Course for Undergraduate Healthcare Students). Students in both years reported spending the most average time on courses related to clinical knowledge (Healthcare Practitioner), followed by financial literacy and management (Professional), diversity management (Collaborator), and priority actions to identify and/or respond to (Health Advocate). The most popular courses related to the Leader and Manager role were around decision-making in human resources, problem-solving, and managing healthcare teams. Based on the top 10 LinkedIn Learning course selections of both cohorts, there appeared to be a preference for courses that were consistent with the role of medical professionals in practice. The most popular LinkedIn Learning course was The Six Morning Habits of High Performers. CONCLUSION: Students gravitated toward courses aligned with their role as professional doctors within the HPCSA competency framework. More studies are needed to understand how medical students develop the six non-clinical roles in the HPCSA framework and the effectiveness of MOOCs in a medical curriculum.


Sujet(s)
COVID-19 , Programme d'études , Enseignement à distance , Enseignement médical premier cycle , Pandémies , Étudiant médecine , Humains , COVID-19/épidémiologie , Enseignement médical premier cycle/méthodes , Enseignement médical premier cycle/organisation et administration , République d'Afrique du Sud , Études transversales , Enseignement à distance/méthodes , SARS-CoV-2 , Femelle , Mâle , Pneumopathie virale/épidémiologie , Infections à coronavirus/épidémiologie
6.
PLoS One ; 19(7): e0302413, 2024.
Article de Anglais | MEDLINE | ID: mdl-38976703

RÉSUMÉ

During the COVID-19 pandemic, pneumonia was the leading cause of respiratory failure and death. In addition to SARS-COV-2, it can be caused by several other bacterial and viral agents. Even today, variants of SARS-COV-2 are endemic and COVID-19 cases are common in many places. The symptoms of COVID-19 are highly diverse and robust, ranging from invisible to severe respiratory failure. Current detection methods for the disease are time-consuming and expensive with low accuracy and precision. To address such situations, we have designed a framework for COVID-19 and Pneumonia detection using multiple deep learning algorithms further accompanied by a deployment scheme. In this study, we have utilized four prominent deep learning models, which are VGG-19, ResNet-50, Inception V3 and Xception, on two separate datasets of CT scan and X-ray images (COVID/Non-COVID) to identify the best models for the detection of COVID-19. We achieved accuracies ranging from 86% to 99% depending on the model and dataset. To further validate our findings, we have applied the four distinct models on two more supplementary datasets of X-ray images of bacterial pneumonia and viral pneumonia. Additionally, we have implemented a flask app to visualize the outcome of our framework to show the identified COVID and Non-COVID images. The findings of this study will be helpful to develop an AI-driven automated tool for the cost effective and faster detection and better management of COVID-19 patients.


Sujet(s)
COVID-19 , Apprentissage profond , SARS-CoV-2 , Tomodensitométrie , COVID-19/imagerie diagnostique , Humains , Tomodensitométrie/méthodes , SARS-CoV-2/isolement et purification , Pneumopathie virale/imagerie diagnostique , Pandémies , Algorithmes , Pneumopathie infectieuse/imagerie diagnostique , Pneumopathie infectieuse/diagnostic , Infections à coronavirus/imagerie diagnostique , Infections à coronavirus/diagnostic , Internet , Betacoronavirus
7.
BMC Pediatr ; 24(1): 457, 2024 Jul 16.
Article de Anglais | MEDLINE | ID: mdl-39014398

RÉSUMÉ

BACKGROUND: Virus, particularly respiratory tract virus infection is likely to co-occur in children with community-acquired pneumonia (CAP). Study focusing on the association between common viruses coinfection and children with CAP is rare. We aimed to study the association between seven common viruses coinfection and clinical/laboratory indexes in children with CAP. METHODS: Six hundred and eighty-four CAP cases from our hospital were enrolled retrospectively. Seven common viruses, including influenza A (FluA), influenza B (FluB), human parainfluenza virus (HPIV), Esptein-Barr virus (EBV), coxsackie virus (CoxsV), cytomegalovirus (CMV), and herpes simplex virus (HSV) were investigated for their associations with CAP. We analyzed the differences of hospitalization days, white blood cell (WBC), c-reactive protein (CRP), platelet (PLT), erythrocyte sedimentation rate (ESR), procalcitonin (PCT), urine red blood cell (uRBC), blood urea nitrogen (BUN), serum creatinine (Scr), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), creatine kinase (CK) and creatine kinase isoenzyme (CKMB) among different viruses coinfection groups by using one-way ANOVA analysis. The differences of clinical/laboratory indexes between ordinary and severe pneumonia groups, as well as non-virus vs multi co-infection viruses groups, and single vs multi co-infection viruses groups by using independent samples T test. Receiver operating characteristic (ROC) curve analyses were applied to test the the predictive value of the clinical/laboratory parameters for the risk of viruses coinfections among CAP. Binary logistic analysis was performed to test the association between various indexes and viruses co-infection. RESULTS: Eighty-four multiple viruses coinfections yielded different prognosis compared with that in 220 single virus coinfection. CMV coinfection was associated with longest hospitalization days, highest ALT, AST and CKMB level. HSV coinfection was associated with highest WBC count, CRP, ESR, and BUN. EBV coinfection was associated with highest PLT and PCT level. FluB coinfection was associated with highest Scr level. CoxsV coinfection was associated with highest uRBC, LDH and CK level. ROC curve analyses showed that CK had the largest area under the curve (AUC: 0.672, p < 10-4) for the risk of viruses coinfections risk in CAP. Significant association between PLT, uRBC, BUN, CK, and CKMB and virus coinfection risk in CAP was observed. CONCLUSIONS: Multiple viruses coinfections indicated different prognosis. Different viruses coinfection yielded varying degrees of effects on the cardiac, liver, kidney and inflamatory injury in CAP. The alterations of clinical/laboratory parameters, particularly CK may be associated with the risk of viruses coinfections in CAP.


Sujet(s)
Co-infection , Infections communautaires , Pneumopathie virale , Humains , Infections communautaires/virologie , Infections communautaires/épidémiologie , Co-infection/épidémiologie , Femelle , Mâle , Études rétrospectives , Enfant d'âge préscolaire , Enfant , Nourrisson , Pneumopathie virale/complications , Pneumopathie virale/épidémiologie , Pneumopathie virale/virologie
8.
J Trop Pediatr ; 70(4)2024 Jul 13.
Article de Anglais | MEDLINE | ID: mdl-39025514

RÉSUMÉ

OBJECTIVE: To identify the prevalence of respiratory syncytial virus (RSV) in a cohort of children under 5 years of age with World Health Organization (WHO)-defined pneumonia and the factors associated with developing severe RSV-associated community-acquired pneumonia (CAP) in primary care in a single centre in Northern Malawi. METHODS: The BIOmarkers TO diagnose PnEumonia (BIOTOPE) study was a prospective cohort study conducted from March to June 2016 that took place in a primary care centre in Northern Malawi. Data from this study was used to identify the characteristics of children under 5 years of age who presented with RSV and WHO-defined CAP. Means, standard deviations, medians and ranges were calculated for continuous variables. A univariate logistic regression was performed to examine the potential predictor variables. RESULTS: Four hundred and ninety-four infants presented with CAP and were eligible for inclusion in the study; RSV infection was detected in 205 (41.6%) of the infants. Eight factors were associated with increased risk for RSV CAP in the univariate model: age, born at term, presenting for care in June, crowded living environment, not being exclusively breastfed, not having received zinc or vitamin A supplementation in the last six months. Infants with RSV were more likely to have an oxygen saturation ≤92% compared to infants with other causes of pneumonia and more likely to have severe pneumonia as defined by the WHO. CONCLUSION: This study supports that RSV-associated CAP is linked to modifiable and non-modifiable risk factors; further research is indicated to determine which interventions would be most impactful. Developing and implementing an infant or maternal vaccine could be a cost-effective way to prevent RSV-associated CAP and mortality in developing nations. More research is needed to understand seasonal patterns of CAP and research over extended periods can offer valuable insights on host, environmental and pathogen-specific factors that contribute to RSV-associated CAP.


Sujet(s)
Infections communautaires , Soins de santé primaires , Infections à virus respiratoire syncytial , Humains , Infections à virus respiratoire syncytial/épidémiologie , Infections à virus respiratoire syncytial/diagnostic , Malawi/épidémiologie , Mâle , Femelle , Nourrisson , Études prospectives , Infections communautaires/épidémiologie , Infections communautaires/virologie , Enfant d'âge préscolaire , Prévalence , Facteurs de risque , Virus respiratoire syncytial humain/isolement et purification , Nouveau-né , Pneumopathie infectieuse/épidémiologie , Pneumopathie infectieuse/virologie , Pneumopathie infectieuse/diagnostic , Pneumopathie virale/épidémiologie , Pneumopathie virale/diagnostic
9.
Medicine (Baltimore) ; 103(27): e38819, 2024 Jul 05.
Article de Anglais | MEDLINE | ID: mdl-38968457

RÉSUMÉ

The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has manifested with respiratory symptoms and a spectrum of extra-pulmonary complications. Emerging evidence suggests potential impacts on the auditory and vestibular systems, but the extent and nature of these effects in recovered individuals remain unclear. This study aimed to investigate the prevalence and severity of vertigo and hearing impairment in individuals who have recovered from COVID-19 and to identify potential risk factors associated with these sensory symptoms. A cohort of 250 recovered COVID-19 patients was assessed. Standardized questionnaires, including the Dizziness Handicap Inventory and the Vertigo Symptom Scale, were used to evaluate vertigo. Hearing assessment was conducted using pure-tone audiometry, speech audiometry, tympanometry, and oto-acoustic emissions testing. Logistic regression analysis was performed to assess the association between COVID-19 severity and the occurrence of sensory symptoms, controlling for confounding variables such as age and comorbidities. Of the participants, 10% reported vertigo, varying severity. Hearing assessments revealed that most participants had normal hearing, with an average speech discrimination score of 94.6. Logistic regression analysis indicated a significant association between severe COVID-19 and an increased likelihood of vertigo (OR 2.11, 95% CI 1.02-4.35, P = .043) and hearing impairment (OR 3.29, 95% CI 1.60-6.78, P = .002). This study suggests a significant association between COVID-19 severity and vertigo and hearing impairment prevalence. The findings underscore the importance of sensory symptom assessment in the post-recovery phase of COVID-19, highlighting the need for comprehensive healthcare approaches to manage long-term sequelae.


Sujet(s)
COVID-19 , Perte d'audition , SARS-CoV-2 , Vertige , Humains , COVID-19/complications , COVID-19/épidémiologie , Vertige/épidémiologie , Vertige/étiologie , Mâle , Femelle , Adulte d'âge moyen , Perte d'audition/épidémiologie , Perte d'audition/étiologie , Adulte , Pandémies , Sujet âgé , Prévalence , Indice de gravité de la maladie , Pneumopathie virale/complications , Pneumopathie virale/épidémiologie , Infections à coronavirus/complications , Infections à coronavirus/épidémiologie , Facteurs de risque , Betacoronavirus
10.
Epidemiol Mikrobiol Imunol ; 73(2): 98-105, 2024.
Article de Anglais | MEDLINE | ID: mdl-39060100

RÉSUMÉ

The novel personal protection equipment based on a face mask equipped with a nanofiber filter functionalized with povidone iodine has been developed and tested in a clinical trial. This nanofiber filter was characterized with a low flow resistance and, thus, allowed comfortable breathing. The performed study proved that the novel nanofiber filter with incorporated povidone-iodine was characterized with a slow release of iodine which minimized side effects but kept disinfection efficiency. Our clinical study performed on 207 positively tested SARS-CoV-2 patients wearing the PPE for 4-8 hours daily for 1 to 4 days has shown that even the iodine amount as low as 0.00028 ppm was sufficient to significantly decrease the reproduction number and, very importantly, to protect against severe course of disease.


Sujet(s)
COVID-19 , Nanofibres , Povidone iodée , SARS-CoV-2 , Povidone iodée/usage thérapeutique , Povidone iodée/administration et posologie , COVID-19/prévention et contrôle , Humains , Pandémies/prévention et contrôle , Pneumopathie virale/prévention et contrôle , Infections à coronavirus/prévention et contrôle , Betacoronavirus , Anti-infectieux locaux/administration et posologie , Mâle , Femelle , Adulte , Masques , Équipement de protection individuelle , Adulte d'âge moyen
11.
Sci Rep ; 14(1): 17201, 2024 Jul 26.
Article de Anglais | MEDLINE | ID: mdl-39060420

RÉSUMÉ

High-dose inhaled Nitric Oxide (iNO) has been shown to have anti-inflammatory, vasodilator, and antimicrobial properties, resulting in improved arterial oxygenation as well as a beneficial therapeutic effect on lower respiratory tract infections. This study evaluated the safety and efficacy of 150-ppm intermittent iNO administered with a novel iNO-generator, for treating adults hospitalised for viral pneumonia. In this prospective, open-label, multicenter study, subjects aged 18-80, diagnosed with viral pneumonia received either standard supportive treatment alone (Control-Group) or combined with iNO for 40 min, 4 times per day up to 7 days (Treatment-Group). Out of 40 recruited subjects, 35 were included in the intention-to-treat population (34 with COVID-19). Adverse Events rate was similar between the groups (56.3% vs. 42.1%; respectively). No treatment-related adverse events were reported, while 2 serious adverse events were accounted for by underlying pre-existing conditions. Among the Treatment-Group, oxygen support duration was reduced by 2.7 days (Hazard Ratio = 2.8; p = 0.0339), a greater number of subjects reached oxygen saturation ≥ 93% within hospitalisation period (Hazard Ratio = 5.4; p = 0.049), and a trend for earlier discharge was demonstrated. Intermittent 150-ppm iNO-treatment is well-tolerated, safe, and beneficial compared to usual care for spontaneously breathing hospitalised adults diagnosed with COVID-19 viral pneumonia.


Sujet(s)
Traitements médicamenteux de la COVID-19 , COVID-19 , Monoxyde d'azote , Humains , Monoxyde d'azote/administration et posologie , Mâle , Femelle , Administration par inhalation , Adulte d'âge moyen , Sujet âgé , Adulte , Études prospectives , SARS-CoV-2 , Sujet âgé de 80 ans ou plus , Pneumopathie virale/traitement médicamenteux , Pneumopathie virale/virologie , Résultat thérapeutique , Jeune adulte , Adolescent
12.
J Infect Public Health ; 17(8): 102496, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38991412

RÉSUMÉ

BACKGROUND: Italy has been the first European Country dealing with SARS-CoV-2, whose diffusion on the territory has not been homogeneous. Among Italian regions, Sardinia represented one of the lowest incidence areas, likely due to its insular nature. Despite this, the impact of insularity on SARS-CoV-2 genetic diversity has not been comprehensively described. METHODS: In the present study, we performed the high throughput sequencing of 888 SARS-CoV-2 genomes collected in Sardinia during the first 23 months of pandemics. In addition, 1439 high-coverage SARS-CoV-2 genomes circulating in Sardinia along three years (December 2019 - January 2023) were downloaded from GISAID, for a total of 2327 viral sequences that were characterized in terms of phylogeny and genomic diversity. RESULTS: Overall, COVID-19 pandemic in Sardinia showed substantial differences with respect to the national panorama, with additional peaks of infections and uncommon lineages that reflects the national and regional policies of re-opening and the subsequent touristic arrivals. Sardinia has been interested by the circulation of at least 87 SARS-CoV-2 lineages, including some that were poorly represented at national and European level, likely linked to multiple importation events. The relative frequency of Sardinian SARS-CoV-2 lineages has been compared to other Mediterranean Islands, revealing a unique composition. CONCLUSIONS: The genomic diversity of SARS-CoV-2 in Sardinia has been shaped by a complex interplay of insular geography, low population density, and touristic arrivals, leading on the one side to the importation of lineages remaining rare at the national level, and resulting on the other side in the delayed entry of otherwise common variants.


Sujet(s)
COVID-19 , Génome viral , Pandémies , Phylogenèse , SARS-CoV-2 , COVID-19/épidémiologie , COVID-19/virologie , Humains , Italie/épidémiologie , SARS-CoV-2/génétique , Variation génétique , Séquençage nucléotidique à haut débit , Pneumopathie virale/épidémiologie , Pneumopathie virale/virologie , Betacoronavirus/génétique
13.
BMJ ; 386: e078918, 2024 07 24.
Article de Anglais | MEDLINE | ID: mdl-39048132

RÉSUMÉ

OBJECTIVE: To evaluate the personal protective effects of wearing versus not wearing surgical face masks in public spaces on self-reported respiratory symptoms over a 14 day period. DESIGN: Pragmatic randomised superiority trial. SETTING: Norway. PARTICIPANTS: 4647 adults aged ≥18 years: 2371 were assigned to the intervention arm and 2276 to the control arm. INTERVENTIONS: Participants in the intervention arm were assigned to wear a surgical face mask in public spaces (eg, shopping centres, streets, public transport) over a 14 day period (mask wearing at home or work was not mentioned). Participants in the control arm were assigned to not wear a surgical face mask in public places. MAIN OUTCOME MEASURES: The primary outcome was self-reported respiratory symptoms consistent with a respiratory infection. Secondary outcomes included self-reported and registered covid-19 infection. RESULTS: Between 10 February 2023 and 27 April 2023, 4647 participants were randomised of whom 4575 (2788 women (60.9%); mean age 51.0 (standard deviation 15.0) years) were included in the intention-to-treat analysis: 2313 (50.6%) in the intervention arm and 2262 (49.4%) in the control arm. 163 events (8.9%) of self-reported symptoms consistent with respiratory infection were reported in the intervention arm and 239 (12.2%) in the control arm. The marginal odds ratio was 0.71 (95% confidence interval (CI) 0.58 to 0.87; P=0.001) favouring the face mask intervention. The absolute risk difference was -3.2% (95% CI -5.2% to -1.3%; P<0.001). No statistically significant effect was found on self- reported (marginal odds ratio 1.07, 95% CI 0.58 to 1.98; P=0.82) or registered covid-19 infection (effect estimate and 95% CI not estimable owing to lack of events in the intervention arm). CONCLUSION: Wearing a surgical face mask in public spaces over 14 days reduces the risk of self-reported symptoms consistent with a respiratory infection, compared with not wearing a surgical face mask. TRIAL REGISTRATION: ClinicalTrials.gov NCT05690516.


Sujet(s)
COVID-19 , Masques , SARS-CoV-2 , Autorapport , Humains , Femelle , Mâle , COVID-19/prévention et contrôle , COVID-19/épidémiologie , Adulte d'âge moyen , Norvège/épidémiologie , Adulte , Infections de l'appareil respiratoire/prévention et contrôle , Sujet âgé , Pandémies/prévention et contrôle , Infections à coronavirus/prévention et contrôle , Infections à coronavirus/épidémiologie , Infections à coronavirus/transmission , Pneumopathie virale/prévention et contrôle , Pneumopathie virale/épidémiologie , Pneumopathie virale/transmission , Betacoronavirus
14.
Front Endocrinol (Lausanne) ; 15: 1342204, 2024.
Article de Anglais | MEDLINE | ID: mdl-38948513

RÉSUMÉ

Purpose: Chest computed tomography (CT) is used to determine the severity of COVID-19 pneumonia, and pneumonia is associated with hyponatremia. This study aims to explore the predictive value of the semi-quantitative CT visual score for hyponatremia in patients with COVID-19 to provide a reference for clinical practice. Methods: In this cross-sectional study, 343 patients with RT-PCR confirmed COVID-19, all patients underwent CT, and the severity of lung lesions was scored by radiologists using the semi-quantitative CT visual score. The risk factors of hyponatremia in COVID-19 patients were analyzed and combined with laboratory tests. The thyroid function changes caused by SARS-CoV-2 infection and their interaction with hyponatremia were also analyzed. Results: In patients with SARS-CoV-2 infection, the total severity score (TSS) of hyponatremia was higher [M(range), 3.5(2.5-5.5) vs 3.0(2.0-4.5) scores, P=0.001], implying that patients with hyponatremia had more severe lung lesions. The risk factors of hyponatremia in the multivariate regression model included age, vomiting, neutrophils, platelet, and total severity score. SARS-CoV-2 infection impacted thyroid function, and patients with hyponatremia showed a lower free triiodothyronine (3.1 ± 0.9 vs 3.7 ± 0.9, P=0.001) and thyroid stimulating hormone level [1.4(0.8-2.4) vs 2.2(1.2-3.4), P=0.038]. Conclusion: Semi-quantitative CT score can be used as a risk factor for hyponatremia in patients with COVID-19. There is a weak positive correlation between serum sodium and free triiodothyronine in patients with SARS-CoV-2 infection.


Sujet(s)
COVID-19 , Hyponatrémie , SARS-CoV-2 , Indice de gravité de la maladie , Tomodensitométrie , Humains , COVID-19/complications , COVID-19/imagerie diagnostique , Hyponatrémie/étiologie , Études transversales , Mâle , Femelle , Adulte d'âge moyen , Facteurs de risque , Tomodensitométrie/méthodes , Sujet âgé , Adulte , Pneumopathie virale/complications , Pneumopathie virale/imagerie diagnostique , Infections à coronavirus/complications , Infections à coronavirus/imagerie diagnostique , Pandémies , Betacoronavirus , Sujet âgé de 80 ans ou plus
15.
PLoS Med ; 21(7): e1004422, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-39008529

RÉSUMÉ

BACKGROUND: Evidence suggests reduced survival rates following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in people with preexisting mental disorders, especially psychotic disorders, before the broad introduction of vaccines. It remains unknown whether this elevated mortality risk persisted at later phases of the pandemic and when accounting for the confounding effect of vaccination uptake and clinically recorded physical comorbidities. METHODS AND FINDINGS: We used data from Czech national health registers to identify first-ever serologically confirmed SARS-CoV-2 infections in 5 epochs related to different phases of the pandemic: 1st March 2020 to 30th September 2020, 1st October 2020 to 26th December 2020, 27th December 2020 to 31st March 2021, 1st April 2021 to 31st October 2021, and 1st November 2021 to 29th February 2022. In these people, we ascertained cases of mental disorders using 2 approaches: (1) per the International Classification of Diseases 10th Revision (ICD-10) diagnostic codes for substance use, psychotic, affective, and anxiety disorders; and (2) per ICD-10 diagnostic codes for the above mental disorders coupled with a prescription for anxiolytics/hypnotics/sedatives, antidepressants, antipsychotics, or stimulants per the Anatomical Therapeutic Chemical (ATC) classification codes. We matched individuals with preexisting mental disorders with counterparts who had no recorded mental disorders on age, sex, month and year of infection, vaccination status, and the Charlson Comorbidity Index (CCI). We assessed deaths with Coronavirus Disease 2019 (COVID-19) and from all-causes in the time period of 28 and 60 days following the infection using stratified Cox proportional hazards models, adjusting for matching variables and additional confounders. The number of individuals in matched-cohorts ranged from 1,328 in epoch 1 to 854,079 in epoch 5. The proportion of females ranged from 34.98% in people diagnosed with substance use disorders in epoch 3 to 71.16% in individuals diagnosed and treated with anxiety disorders in epoch 5. The mean age ranged from 40.97 years (standard deviation [SD] = 15.69 years) in individuals diagnosed with substance use disorders in epoch 5 to 56.04 years (SD = 18.37 years) in people diagnosed with psychotic disorders in epoch 2. People diagnosed with or diagnosed and treated for psychotic disorders had a consistently elevated risk of dying with COVID-19 in epochs 2, 3, 4, and 5, with adjusted hazard ratios (aHRs) ranging from 1.46 [95% confidence intervals (CIs), 1.18, 1.79] to 1.93 [95% CIs, 1.12, 3.32]. This patient group demonstrated also a consistently elevated risk of all-cause mortality in epochs 2, 3, 4, and 5 (aHR from 1.43 [95% CIs, 1.23, 1.66] to 1.99 [95% CIs, 1.25, 3.16]). The models could not be reliably fit for psychotic disorders in epoch 1. People diagnosed with substance use disorders had an increased risk of all-cause mortality 28 days postinfection in epoch 3, 4, and 5 (aHR from 1.30 [95% CIs, 1.14, 1.47] to 1.59 [95% CIs, 1.19, 2.12]) and 60 days postinfection in epoch 2, 3, 4, and 5 (aHR from 1.22 [95% CIs, 1.08, 1.38] to 1.52 [95% CIs, 1.16, 1.98]). Cases ascertained based on diagnosis of substance use disorders and treatment had increased risk of all-cause mortality in epoch 2, 3, 4, and 5 (aHR from 1.22 [95% CIs, 1.03, 1.43] to 1.91 [95% CIs, 1.25, 2.91]). The models could not be reliably fit for substance use disorders in epoch 1. In contrast to these, people diagnosed with anxiety disorders had a decreased risk of death with COVID-19 in epoch 2, 3, and 5 (aHR from 0.78 [95% CIs, 0.69, 0.88] to 0.89 [95% CIs, 0.81, 0.98]) and all-cause mortality in epoch 2, 3, 4, and 5 (aHR from 0.83 [95% CIs, 0.77, 0.90] to 0.88 [95% CIs, 0.83, 0.93]). People diagnosed and treated for affective disorders had a decreased risk of both death with COVID-19 and from all-causes in epoch 3 (aHR from 0.87 [95% CIs, 0.79, 0.96] to 0.90 [95% CIs, 0.83, 0.99]), but demonstrated broadly null effects in other epochs. Given the unavailability of data on a number of potentially influential confounders, particularly body mass index, tobacco smoking status, and socioeconomic status, part of the detected associations might be due to residual confounding. CONCLUSIONS: People with preexisting psychotic, and, less robustly, substance use disorders demonstrated a persistently elevated risk of death following SARS-CoV-2 infection throughout the pandemic. While it cannot be ruled out that part of the detected associations is due to residual confounding, this excess mortality cannot be fully explained by lower vaccination uptake and more clinically recorded physical comorbidities in these patient groups.


Sujet(s)
COVID-19 , Troubles mentaux , Pandémies , SARS-CoV-2 , Humains , COVID-19/mortalité , COVID-19/épidémiologie , COVID-19/complications , Femelle , Mâle , Troubles mentaux/épidémiologie , Adulte d'âge moyen , Adulte , République tchèque/épidémiologie , Études de cohortes , Sujet âgé , Comorbidité , Pneumopathie virale/mortalité , Pneumopathie virale/épidémiologie , Pneumopathie virale/complications , Jeune adulte , Infections à coronavirus/mortalité , Infections à coronavirus/épidémiologie , Infections à coronavirus/complications , Betacoronavirus , Cause de décès , Enregistrements , Adolescent
16.
J Zhejiang Univ Sci B ; 25(7): 628-632, 2024 Jul 15.
Article de Anglais | MEDLINE | ID: mdl-39011682

RÉSUMÉ

Airborne transmission is among the most frequent types of nosocomial infection. Recent years have witnessed frequent outbreaks of airborne diseases, such as severe acute respiratory syndrome (SARS) in 2002, Middle East respiratory syndrome (MERS) in 2012, and coronavirus disease 2019 (COVID-19), with the latter being on the rampage since the end of 2019 and bringing the effect of aerosols on health back to the fore (Gralton et al., 2011; Wang et al., 2021). An increasing number of studies have shown that certain highly transmissible pathogens can maintain long-term stability and efficiently spread through aerosols (Leung, 2021; Lv et al., 2021). As reported previously, influenza viruses that can spread efficiently through aerosols remain stable for a longer period compared to those that cannot. The World Health Organization (WHO) has stated that aerosol-generating procedures (AGPs) play an important role in aerosol transmission in hospitals (Calderwood et al., 2021). AGPs, referring to medical procedures that produce aerosols, including dental procedures, endotracheal intubation, sputum aspiration, and laparoscopic surgeries, have been reported to be significantly associated with an increased risk of nosocomial infection among medical personnel (Hamilton, 2021).


Sujet(s)
Aérosols , COVID-19 , Infection croisée , Endoscopes , SARS-CoV-2 , Humains , Infection croisée/transmission , Infection croisée/prévention et contrôle , COVID-19/transmission , SARS-CoV-2/isolement et purification , Pandémies , Infections à coronavirus/transmission , Pneumopathie virale/transmission , Désinfection/méthodes , Betacoronavirus , Microbiologie de l'air
17.
Front Endocrinol (Lausanne) ; 15: 1345008, 2024.
Article de Anglais | MEDLINE | ID: mdl-39045269

RÉSUMÉ

Introduction: This study aimed to determine the frequency of thyroid gland involvement in chest CT scans of patients with COVID-19 admitted to university-affiliated hospitals and assess its relationship with the severity of lung involvement and patient survival in 2020. Material and methods: In this retrospective cross-sectional study, 1000 PCR-positive patients with COVID-19 who were referred to University-affiliated Hospital in 2020 and had chest CT performed within 72 hours of admission to the hospital were examined. The data was collected by patient file information and CT findings recorded in the PACS system, including thyroid involvement, the severity of lung involvement, and findings related to the death and recovery of patients. Results: The mean age of the examined patients was 56 years. 525 people (52.5%) were men, and 475 (47.5%) were women. 14% had severe pulmonary involvement, and 9.3% had very severe involvement. Moreover, 15.9 percent of them had deceased. 19.7% had focal thyroid involvement, 14% had diffuse involvement, and 66.3% were healthy subjects. Male gender and older age showed a significant relationship with thyroid gland involvement. The severity of lung involvement, the death rate in patients, and hospitalization in ICU were also significantly related to thyroid gland involvement in patients with COVID. Discussion and conclusion: This study highlights the importance of considering thyroid-gland involvement in the comprehensive management of COVID-19 patients. Routine screening and monitoring of thyroid-function may facilitate earlier detection and appropriate management of thyroid-related complications, potentially improving clinical outcomes. This study suggests that in COVID-19 infection the monitoring of thyroid function is prudent, particularly in cases of more serious disease.


Sujet(s)
COVID-19 , SARS-CoV-2 , Indice de gravité de la maladie , Tomodensitométrie , Humains , COVID-19/imagerie diagnostique , COVID-19/mortalité , COVID-19/épidémiologie , Mâle , Femelle , Adulte d'âge moyen , Études rétrospectives , Tomodensitométrie/méthodes , Études transversales , Sujet âgé , Adulte , Glande thyroide/imagerie diagnostique , Glande thyroide/anatomopathologie , Poumon/imagerie diagnostique , Pneumopathie virale/imagerie diagnostique , Pneumopathie virale/mortalité , Pneumopathie virale/épidémiologie , Pandémies , Maladies de la thyroïde/imagerie diagnostique , Maladies de la thyroïde/épidémiologie , Infections à coronavirus/imagerie diagnostique , Infections à coronavirus/mortalité , Infections à coronavirus/épidémiologie , Betacoronavirus/isolement et purification , Taux de survie
18.
J Cardiothorac Surg ; 19(1): 442, 2024 Jul 13.
Article de Anglais | MEDLINE | ID: mdl-39003456

RÉSUMÉ

BACKGROUND: The COVID-19 pandemic was primarily considered a respiratory malady in the early phases of the outbreak. However, as more patients suffer from this illness, a myriad of symptoms emerge in organ systems separate from the lungs. Among those patients with cardiac involvement, myocarditis, pericarditis, myocardial infarction, and arrhythmia were among the most common manifestations. Pericarditis with pericardial effusion requiring medical or interventional treatments has been previously reported in the acute setting. Notably, chronic pericarditis with pericardial thickening resulting in constriction requiring sternotomy and pericardiectomy has not been published to date. CASE PRESENTATION: A patient with COVID-19-associated constrictive pericarditis three years after viral infection requiring pericardiectomy was reported. The COVID-19 infection originally manifested as anosmia and ageusia. Subsequently, the patient developed dyspnea, fatigue, right-sided chest pressure, bilateral leg edema, and abdominal fullness. Following recurrent right pleural effusions and a negative autoimmune work-up, the patient was referred for cardiothoracic surgery for pericardiectomy when radiographic imaging and hemodynamic assessment were consistent with constrictive pericarditis. Upon median sternotomy, the patient's pericardium was measured to be 8 mm thick. Descriptions of the clinical, diagnostic, and therapeutic features are provided. Within the first week after the operation, the patient's dyspnea resolved; one month later, leg edema and abdominal bloating were relieved. CONCLUSIONS: Although an association between COVID-19 and cardiac complications has been established, this case adds another element of virus severity and chronic manifestations. The need for sternotomy and pericardiectomy to treat COVID-19-related constrictive pericarditis is believed to be the first reported diagnosis.


Sujet(s)
COVID-19 , Péricardectomie , Péricardite constrictive , SARS-CoV-2 , Humains , Péricardite constrictive/chirurgie , Péricardite constrictive/diagnostic , COVID-19/complications , Péricardectomie/méthodes , Mâle , Pandémies , Pneumopathie virale/complications , Infections à coronavirus/complications , Adulte d'âge moyen , Betacoronavirus , Tomodensitométrie
19.
Database (Oxford) ; 20242024 Jul 26.
Article de Anglais | MEDLINE | ID: mdl-39066515

RÉSUMÉ

Biological databases serve as critical basics for modern research, and amid the dynamic landscape of biology, the COVID-19 database has emerged as an indispensable resource. The global outbreak of Covid-19, commencing in December 2019, necessitates comprehensive databases to unravel the intricate connections between this novel virus and cancer. Despite existing databases, a crucial need persists for a centralized and accessible method to acquire precise information within the research community. The main aim of the work is to develop a database which has all the COVID-19-related data available in just one click with auto global notifications. This gap is addressed by the meticulously designed COVID-19 Pandemic Database (CO-19 PDB 2.0), positioned as a comprehensive resource for researchers navigating the complexities of COVID-19 and cancer. Between December 2019 and June 2024, the CO-19 PDB 2.0 systematically collected and organized 120 datasets into six distinct categories, each catering to specific functionalities. These categories encompass a chemical structure database, a digital image database, a visualization tool database, a genomic database, a social science database, and a literature database. Functionalities range from image analysis and gene sequence information to data visualization and updates on environmental events. CO-19 PDB 2.0 has the option to choose either the search page for the database or the autonotification page, providing a seamless retrieval of information. The dedicated page introduces six predefined charts, providing insights into crucial criteria such as the number of cases and deaths', country-wise distribution, 'new cases and recovery', and rates of death and recovery. The global impact of COVID-19 on cancer patients has led to extensive collaboration among research institutions, producing numerous articles and computational studies published in international journals. A key feature of this initiative is auto daily notifications for standardized information updates. Users can easily navigate based on different categories or use a direct search option. The study offers up-to-date COVID-19 datasets and global statistics on COVID-19 and cancer, highlighting the top 10 cancers diagnosed in the USA in 2022. Breast and prostate cancers are the most common, representing 30% and 26% of new cases, respectively. The initiative also ensures the removal or replacement of dead links, providing a valuable resource for researchers, healthcare professionals, and individuals. The database has been implemented in PHP, HTML, CSS and MySQL and is available freely at https://www.co-19pdb.habdsk.org/. Database URL: https://www.co-19pdb.habdsk.org/.


Sujet(s)
COVID-19 , Tumeurs , Pandémies , SARS-CoV-2 , COVID-19/épidémiologie , COVID-19/virologie , Humains , Tumeurs/épidémiologie , Bases de données factuelles , Infections à coronavirus/épidémiologie , Infections à coronavirus/virologie , Pneumopathie virale/épidémiologie , Pneumopathie virale/virologie , Betacoronavirus , Bases de données de protéines
20.
BMC Pulm Med ; 24(1): 372, 2024 Jul 31.
Article de Anglais | MEDLINE | ID: mdl-39085852

RÉSUMÉ

BACKGROUND: The aim of this retrospective study was to examine the risk factors of positive lower respiratory tract cultures and to investigate whether nosocomial infections are common in patients with positive lower respiratory tract cultures. METHODS: We enrolled 86 patients diagnosed with influenza A-related critical illness who were treated at Fuzhou Pulmonary Hospital of Fujian in China between 1st October 2013 and 31st March 2019. The of admission were used to divide the enrolled patients into two groups. Sputum and bronchoalveolar lavage fluid specimens were collected within 48 h after admission for culture. All samples were cultured immediately after sampling. Nosocomial infections are defined as any symptom or sign of pulmonary infiltration, confirmed by X-ray, after 5 days of admission and positive results from one or more cultures. RESULTS: The average age of this cohort was (54.13 ± 16.52) years. Based on the culture results, Staphylococcus aureus and Candida albicans had the highest positive rates (3.40% (3/86) and 20.90% (18/86), respectively). In patients with positive lower respiratory tract cultures, the incidence of nosocomial infection was 73.30% (22/30) five days after admission. However, the incidence of nosocomial infection was lower (42.80%, 24/56) in patients with negative lower respiratory tract cultures. Hemoptysis, systolic pressure at admission, and blood urea nitrogen level at admission were all independent risk factors for positive lower respiratory tract cultures within 48 h of admission. CONCLUSION: Our data showed that a significant proportion of patients with pneumonia exhibited co-infections with bacteria or fungi within five days of hospital admission. Hemoptysis, systolic pressure, and blood urea nitrogen levels at admission emerged as the key risk factors. These findings underscore the necessity of closely monitoring patients with influenza infection, particularly for positive bacterial or fungal cultures within the initial 48 h of admission.


Sujet(s)
Liquide de lavage bronchoalvéolaire , Infection croisée , Pneumopathie virale , Humains , Mâle , Adulte d'âge moyen , Femelle , Études rétrospectives , Sujet âgé , Infection croisée/microbiologie , Infection croisée/épidémiologie , Chine/épidémiologie , Facteurs de risque , Adulte , Liquide de lavage bronchoalvéolaire/microbiologie , Liquide de lavage bronchoalvéolaire/virologie , Pneumopathie virale/complications , Pneumopathie virale/diagnostic , Expectoration/microbiologie , Grippe humaine/complications , Staphylococcus aureus/isolement et purification , Incidence , Pertinence clinique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE